Halma buys Dreampath for up to €275m

(Sharecast News) - Safety equipment maker Halma on Tuesday said it had bought France-based Dreampath Diagnostics for an initial €154m (£132m), on a cash- and debt-free basis. Headquartered in Strasbourg, France, Dreampath makes automated systems that enable anatomical pathology laboratories to track, store and manage patient tissue samples throughout the diagnostic process.

The deal includes an earn-out of up to €121m (£104m), based on performance over the two years to 31 March 2027 and 2028.

Dreampath's revenue for the 12 months to 31 March 2027 is forecast to be €33m (approximately £28m).

This acquisition boosts Halma's Healthcare sector by adding expertise in tissue sample traceability, archiving, and lifecycle management, enhancing its existing Healthcare Enablement portfolio. Dreampath will continue to run as an independent company within the Healthcare Sector, guided by its current leadership team.

Reporting by Frank Prenesti for Sharecast.com